AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28887274 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative MRI measure for muscle fat infiltration (MFI)
Number of subjects: 62
Study 28887274 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 62
Study 28887274 — intervention group
Group type: EXPERIMENTAL
Intervention: WAD participants (mild or moderate and severe)
Number of subjects: 62
Study 27693004 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg)
Number of subjects: 990
Study 27693004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 990
Study 27693004 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (general)
Number of subjects: 990
Study 27693004 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clinical risk profile and CAC score
Number of subjects: 990
Study 25650378 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral secondhand smoke (SHS) reduction program
Number of subjects: 71
Study 25650378 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 71
Study 23625945 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 2737
Study 23625945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2737
Study 21114352 — intervention group
Group type: EXPERIMENTAL
Intervention: Interacting with a prejudiced partner (compared to unprejudiced partner) for members of stigmatized groups who believe the status system is fair.
Number of subjects: 2
Study 21114352 — intervention group
Group type: EXPERIMENTAL
Intervention: Interacting with a prejudiced partner (compared to unprejudiced partner) for members of stigmatized groups who believe the status system is unfair.
Number of subjects: 2
Study 19039466 — intervention group
Group type: EXPERIMENTAL
Intervention: 14% duty cycle (n=21)
Number of subjects: 32
Study 19039466 — intervention group
Group type: EXPERIMENTAL
Intervention: 67% duty cycle (n=17)
Number of subjects: 32
Study 19039466 — intervention group
Group type: COMPARATOR
Intervention: Both groups (14% and 67% duty cycles)
Number of subjects: 32
Study 19039466 — intervention group
Group type: COMPARATOR
Intervention: Both cycles
Number of subjects: 32
Study 16635922 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligo-antigenic diet
Number of subjects: 4
Study 16635922 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPFC challenge
Number of subjects: 4
Study 16635922 — intervention group
Group type: COMPARATOR
Intervention: Food hypersensitivity
Number of subjects: 4
Study 16635922 — intervention group
Group type: COMPARATOR
Intervention: Histological examination
Number of subjects: 4
Study 12913325 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose regulation (metabolic regulation of diabetes)
Number of subjects: 40
Study 12913325 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched, no specific intervention mentioned)
Number of subjects: 40
Study 10331109 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg daily) with pindolol (7.5 to 10 mg daily)
Number of subjects: 86
Study 10331109 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg daily) with placebo
Number of subjects: 86
Study 10331109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol treatment
Number of subjects: 86
Study 8759902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosupernatant
Number of subjects: 58
Study 8759902 — intervention group
Group type: COMPARATOR
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 58
Study 1884932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology brush and extended‐tip wooden spatula
Number of subjects: 96
Study 1884932 — intervention group
Group type: EXPERIMENTAL
Intervention: Moistened cotton swab and extended‐tip wooden spatula
Number of subjects: 96
Study 1884932 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended‐tip wooden spatula and Ayre blunt spatula
Number of subjects: 96
Study 1884932 — intervention group
Group type: COMPARATOR
Intervention: Strict adherence to a collection protocol
Number of subjects: 96
Study 1884932 — intervention group
Group type: COMPARATOR
Intervention: Education on tools and collection methods
Number of subjects: 96
Study 1884932 — intervention group
Group type: EXPERIMENTAL
Intervention: Widespread use of the cytology brush post-study
Number of subjects: 96
Study 6754923 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyography biofeedback relaxation training
Number of subjects: 3
Study 6754923 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-conductance biofeedback relaxation training
Number of subjects: 3
Study 6754923 — intervention group
Group type: COMPARATOR
Intervention: Normal antenatal classes
Number of subjects: 3
Study 31093618 — intervention group
Group type: EXPERIMENTAL
Intervention: Venus Bulk Fill (flowable bulk-fill composite)
Number of subjects: 32
Study 31093618 — intervention group
Group type: COMPARATOR
Intervention: Dyract eXtra (compomer)
Number of subjects: 32
Study 28419068 — intervention group
Group type: EXPERIMENTAL
Intervention: TX‐004HR 4, 10, and 25 μg
Number of subjects: 0
Study 28419068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25384338 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide
Number of subjects: 146
Study 25384338 — intervention group
Group type: EXPERIMENTAL
Intervention: marimastat
Number of subjects: 146
Study 25384338 — intervention group
Group type: EXPERIMENTAL
Intervention: ATN-224
Number of subjects: 146
Study 25384338 — intervention group
Group type: EXPERIMENTAL
Intervention: imatinib
Number of subjects: 146
Study 25384338 — intervention group
Group type: EXPERIMENTAL
Intervention: nonhormonal therapy
Number of subjects: 146
Study 23642343 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparins (unfractionated heparin, heparinoids, or low-molecular-weight heparin)
Number of subjects: 0
Study 23642343 — intervention group
Group type: COMPARATOR
Intervention: Aspirin or placebo
Number of subjects: 0
Study 21396310 — intervention group
Group type: COMPARATOR
Intervention: Standard laparoscopic instruments and port position
Number of subjects: 14
Study 21396310 — intervention group
Group type: EXPERIMENTAL
Intervention: SILS with angulated instruments
Number of subjects: 14
Study 21396310 — intervention group
Group type: EXPERIMENTAL
Intervention: SILS with straight instruments
Number of subjects: 14
Study 21396310 — intervention group
Group type: EXPERIMENTAL
Intervention: SILS (both angulated and straight instruments)
Number of subjects: 14
Study 19799788 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding regimen (commencing milk feeds on day 2 after birth)
Number of subjects: 400
Study 19799788 — intervention group
Group type: COMPARATOR
Intervention: Late enteral feeding regimen (commencing milk feeds on day 6 after birth)
Number of subjects: 400
Study 19759996 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) 3 times per week for 12 weeks
Number of subjects: 0
Study 19759996 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE) 3 times per week for 12 weeks
Number of subjects: 0
Study 19759996 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (CON)
Number of subjects: 0
Study 15179231 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-driven ventilator weaning
Number of subjects: 0
Study 11323369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg/kg with ondansetron 0.1 mg/kg
Number of subjects: 0
Study 11323369 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 1 mg/kg with placebo
Number of subjects: 0
Study 9338667 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2.0% dorzolamide hydrochloride
Number of subjects: 210
Study 9338667 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetazolamide (125 mg)
Number of subjects: 210
Study 9338667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 9338667 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide and Acetazolamide (combined comparison)
Number of subjects: 210
Study 7894258 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine for a mean of 30.9 days
Number of subjects: 20
Study 7894258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2966552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose isradipine (0.007 mg/kg)
Number of subjects: 16
Study 2966552 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose isradipine (0.015 mg/kg)
Number of subjects: 16
Study 29929387 — intervention group
Group type: EXPERIMENTAL
Intervention: Feigning condition; PAI malingering indicators using Negative Impression (NIM) and Negative Distortion (NDS) scales
Number of subjects: 0
Study 29929387 — intervention group
Group type: EXPERIMENTAL
Intervention: Defensive condition; Defensive (DEF) index
Number of subjects: 0
Study 29580796 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.025‐0.2 μg/kg/min)
Number of subjects: 90
Study 29580796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 29580796 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 90
Study 28785879 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine 1200 mg
Number of subjects: 45
Study 28785879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 28785879 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 45
Study 26678642 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal approach to improving intensity of follow-up visits
Number of subjects: 0
Study 26678642 — intervention group
Group type: EXPERIMENTAL
Intervention: Early follow-up within 4 weeks of an elevated reading
Number of subjects: 0
Study 23679917 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Arms of the SEYLE project (specific interventions not detailed in the abstract)
Number of subjects: 12395
Study 23679917 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory, Second Edition (BDI‐II)
Number of subjects: 12395
Study 23679917 — intervention group
Group type: EXPERIMENTAL
Intervention: Zung Self‐Rating Anxiety Scale (Z‐SAS)
Number of subjects: 12395
Study 23679917 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths and Difficulties Questionnaire (SDQ)
Number of subjects: 12395
Study 23679917 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization Well‐Being Scale (WHO‐5)
Number of subjects: 12395
Study 21214623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural intervention with Tai Chi
Number of subjects: 0
Study 21214623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural intervention
Number of subjects: 0
Study 21214623 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18708408 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma B(6) (pyridoxal 5'-phosphate)
Number of subjects: 1084
Study 18708408 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma B(2) (riboflavin)
Number of subjects: 1084
Study 18708408 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma B(12)
Number of subjects: 1084
Study 18708408 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of vitamin B(2) and B(6)
Number of subjects: 1084
Study 17068304 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059
Number of subjects: 1722
Study 17068304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1722
Study 12610241 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to pay for depression treatment at baseline
Number of subjects: 615
Study 12610241 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to pay for depression treatment at six-month follow-up
Number of subjects: 615
Study 10638900 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blockade with bupivacaine 0.25%
Number of subjects: 6
Study 10638900 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose infusion (4 mg x kg(‐1) x min(‐1))
Number of subjects: 6
Study 10638900 — intervention group
Group type: COMPARATOR
Intervention: Control (no epidural blockade)
Number of subjects: 6
Study 8866920 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg didanosine as a single agent
Number of subjects: 10
Study 8866920 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg trimethoprim + 1000 mg sulphamethoxazole
Number of subjects: 10
Study 8866920 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg trimethoprim + 200 mg didanosine
Number of subjects: 10
Study 8866920 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg sulphamethoxazole + 200 mg didanosine
Number of subjects: 10
Study 8866920 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg trimethoprim + 1000 mg sulphamethoxazole + 200 mg didanosine
Number of subjects: 10
Study 1996756 — intervention group
Group type: EXPERIMENTAL
Intervention: oesophageal heat exchanger
Number of subjects: 30
Study 1996756 — intervention group
Group type: EXPERIMENTAL
Intervention: overhead radiant heater
Number of subjects: 30
Study 1996756 — intervention group
Group type: COMPARATOR
Intervention: no active rewarming
Number of subjects: 30
Study 6504632 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin E administration (100 mg/kg/d for at least 8 weeks, first dose within 8 hours of life)
Number of subjects: 134
Study 6504632 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 134
Study 30853068 — intervention group
Group type: EXPERIMENTAL
Intervention: Bass brushing method (n=15)
Number of subjects: 30
Study 30853068 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=15)
Number of subjects: 30
Study 29859706 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sonolysis
Number of subjects: 144
Study 29859706 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study 27794259 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Immersion Simulation mattress (high immersion setting)
Number of subjects: 17
Study 27794259 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Immersion Simulation mattress (medium immersion setting)
Number of subjects: 17
Study 27794259 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Immersion Simulation mattress (low immersion setting)
Number of subjects: 17
Study 27794259 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral tilt posture
Number of subjects: 17
Study 27794259 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine posture
Number of subjects: 17
Study 27794259 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sitting posture
Number of subjects: 17
Study 24623104 — intervention group
Group type: EXPERIMENTAL
Intervention: GC1113 intravenous 3-5 μg/kg
Number of subjects: 96
Study 24623104 — intervention group
Group type: EXPERIMENTAL
Intervention: GC1113 subcutaneous 1-8 μg/kg
Number of subjects: 96
Study 24623104 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa 30 μg
Number of subjects: 96
Study 24623104 — intervention group
Group type: EXPERIMENTAL
Intervention: GC1113 intravenous 0.3-5 μg/kg
Number of subjects: 96
Study 22239992 — intervention group
Group type: COMPARATOR
Intervention: IL10G short G20 allele
Number of subjects: 82
Study 22239992 — intervention group
Group type: COMPARATOR
Intervention: Combined haplotypes cH1/cH8 (short G20 + R13 alleles)
Number of subjects: 82
Study 22239992 — intervention group
Group type: COMPARATOR
Intervention: Levels of Abs to PF4 in Ab(pos) patients
Number of subjects: 82
Study 20103509 — intervention group
Group type: EXPERIMENTAL
Intervention: Posthorax support vest (group B)
Number of subjects: 1560
Study 20103509 — intervention group
Group type: COMPARATOR
Intervention: Flexible dressing (group A)
Number of subjects: 1560
Study 18341417 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser treatment (810-nm Ga-Al-As laser, 60 mW, 1.8 J per point, 14.4 J per session, 12 sessions over 8 weeks)
Number of subjects: 63
Study 18341417 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser treatment
Number of subjects: 63
Study 18341417 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 63
Study 15735445 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intrapartum nevirapine (NVP) dose
Number of subjects: 43
Study 12644982 — intervention group
Group type: EXPERIMENTAL
Intervention: ZD1839 250 mg/day
Number of subjects: 431
Study 12644982 — intervention group
Group type: EXPERIMENTAL
Intervention: ZD1839 500 mg/day
Number of subjects: 431
Study 12644982 — intervention group
Group type: EXPERIMENTAL
Intervention: ZD1839 250 mg/day (IDEAL-2)
Number of subjects: 431
Study 12644982 — intervention group
Group type: EXPERIMENTAL
Intervention: ZD1839 500 mg/day (IDEAL-2)
Number of subjects: 431
Study 9660028 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinia melanoma oncolysate (VMO) - 1 U containing 2 mg of total protein derived from 5 x 10(6) melanoma cells and 10(5.6) 50% tissue culture infectious dose of vaccinia virus, administered once a week for 13 weeks and then once every 2 weeks for a total of 12 months.
Number of subjects: 250
Study 9660028 — intervention group
Group type: COMPARATOR
Intervention: Control (V) - 1 U containing 10(5.4) 50% tissue culture infectious dose of vaccinia virus, administered once a week for 13 weeks and then once every 2 weeks for a total of 12 months.
Number of subjects: 250
Study 9660028 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinia melanoma oncolysate (VMO) - in a retrospective subset analysis of male patients aged 44-57 years with one to five positive nodes (n = 20).
Number of subjects: 250
Study 9660028 — intervention group
Group type: COMPARATOR
Intervention: Control (V) - in a retrospective subset analysis of male patients aged 44-57 years with one to five positive nodes (n = 18).
Number of subjects: 250
Study 7752665 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic aerobic training
Number of subjects: 0
Study 7752665 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 0
Study 7752665 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programs
Number of subjects: 0
Study 2676535 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 59
Study 2676535 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 59
Study 2676535 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Sotalol and Amiodarone
Number of subjects: 59
Study 820425 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipedal lymphography and exploratory laparotomy with selective node biopsy
Number of subjects: 50
Study 820425 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 and T2 tumors (Stage B)
Number of subjects: 50
Study 820425 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 tumors (Stage C)
Number of subjects: 50
Study 820425 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorly differentiated tumors
Number of subjects: 50
Study 820425 — intervention group
Group type: EXPERIMENTAL
Intervention: Well‐differentiated tumors
Number of subjects: 50
Study 820425 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory laparotomy
Number of subjects: 50
Study 820425 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lymphatic metastases
Number of subjects: 50
Study 29247405 — intervention group
Group type: EXPERIMENTAL
Intervention: Demoralization
Number of subjects: 0
Study 29247405 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 0
Study 29247405 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (depression and demoralization)
Number of subjects: 0
Study 29247405 — intervention group
Group type: COMPARATOR
Intervention: No affective conditions
Number of subjects: 0
Study 28033031 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition with staff training
Number of subjects: 379
Study 28033031 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not explicitly detailed)
Number of subjects: 379
Study 25795408 — intervention group
Group type: EXPERIMENTAL
Intervention: Linsitinib (150 mg oral, twice daily)
Number of subjects: 139
Study 25795408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 25795408 — intervention group
Group type: EXPERIMENTAL
Intervention: Linsitinib
Number of subjects: 139
Study 24060561 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (4 tablets of 100 mg imatinib)
Number of subjects: 30
Study 24060561 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (1 tablet of 400 mg imatinib)
Number of subjects: 30
Study 24060561 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 30
Study 20199722 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography combined with transthoracic echocardiography (TEE)
Number of subjects: 40
Study 20199722 — intervention group
Group type: COMPARATOR
Intervention: Traditional transcatheter occlusion
Number of subjects: 40
Study 18986387 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m², days 1, 4, 8, and 11 for eight 3-week cycles, then days 1, 8, 15, and 22 for three 5-week cycles)
Number of subjects: 598
Study 18986387 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (40 mg/d, days 1-4, 9-12, and 17-20 for four 5-week cycles, then days 1-4 only for five 4-week cycles)
Number of subjects: 598
Study 16511418 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug regimen
Number of subjects: 105
Study 16511418 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug regimen
Number of subjects: 105
Study 16511418 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor-containing ART
Number of subjects: 105
Study 16511418 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 patients who declined therapy)
Number of subjects: 105
Study 12756389 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' attitudes towards trial participation
Number of subjects: 33
Study 12756389 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental factors influencing trial participation
Number of subjects: 33
Study 12756389 — intervention group
Group type: EXPERIMENTAL
Intervention: Child factors influencing trial participation
Number of subjects: 33
Study 12756389 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial factors influencing trial participation
Number of subjects: 33
Study 12756389 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor factors influencing trial participation
Number of subjects: 33
Study 12756389 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for increasing participation
Number of subjects: 33